In 2013, Han and colleagues analyzed CIMP status based on an extended panel of eight markers (i.e., CACNA1G, CDKN2A, IGF2, MLH1, NEUROG1, RUNX3, SOCS1, and Cellular Retinoic Acid Binding Protein 1 – CRABP1) in CRC patients who received adjuvant therapy with the FOLFOX protocol [53]. Here, CACNA1G is linked to colorectal carcinoma.